Schafer L A, Goldstein A L, Gutterman J U, Hersh E M
Ann N Y Acad Sci. 1976;277(00):609-20. doi: 10.1111/j.1749-6632.1976.tb41733.x.
Thymosin, fraction V, prepared by the method of Goldstein et al., was studied in in vitro lymphocyte cultures with cells obtained from normal subjects and patients with disseminated cancer. Thymosin lowered blastogenic activity in some patients, did not affect it in others, and increased counts in still others. There was a statistically significant depression in baseline (prethymosin) counts from both normals and patients when individuals whose counts increased in the presence of thymosin were compared with other subjects. We conclude that thymosin tended to raise depressed blastogenesis into the normal range without causing supranormal activity or without itself acting as a mitogen or antigen. Eighty-two in vivo courses in thymosin were given to 32 patients. Analysis of the first thymosin courses in these 32 patients shows that immunologic reconstitution occurred in patients with originally depressed T-cell function and numbers, whereas little change was apparent in patients with initially intact tests of T-cell activity. Clinical effects were equivocal; however, no systematic clinical trial was conducted. Toxicity was minimal (four of the 32 patients); in each case, it consisted of inflammation at the injection site. The in vitro and in vivo results of this study suggest that thymosin therapy modulates and partially normalizes T-lymphocyte numbers and function.
采用戈尔茨坦等人的方法制备的胸腺素组分V，在从正常受试者和播散性癌症患者获取的细胞进行的体外淋巴细胞培养中进行了研究。胸腺素在一些患者中降低了增殖活性，在另一些患者中未产生影响，而在其他一些患者中则增加了细胞计数。当将在胸腺素存在下细胞计数增加的个体与其他受试者进行比较时，正常人和患者的基线（胸腺素治疗前）计数均出现了具有统计学意义的降低。我们得出结论，胸腺素倾向于将降低的增殖反应提高到正常范围，而不会引起超正常活性，也不会自身作为有丝分裂原或抗原起作用。对32例患者进行了82次胸腺素体内治疗疗程。对这32例患者的首次胸腺素疗程分析表明，最初T细胞功能和数量降低的患者发生了免疫重建，而最初T细胞活性检测正常的患者几乎没有明显变化。临床效果不明确；然而，未进行系统的临床试验。毒性极小（32例患者中有4例）；在每种情况下，毒性均表现为注射部位炎症。本研究的体外和体内结果表明，胸腺素疗法可调节T淋巴细胞数量和功能并使其部分恢复正常。
